Peptide Bioavailability Explained: Oral vs Injection vs Nasal

Bioavailability refers to the fraction of an administered substance that reaches systemic circulation in an active form. For intravenous (IV) injection, bioavailability is by definition 100% — the substance enters the bloodstream directly. All other routes are compared against this benchmark.

For peptides, bioavailability is a critical concern because peptides are inherently fragile molecules. They are chains of amino acids held together by peptide bonds — the same bonds that digestive enzymes are specifically designed to break. This fundamental biology creates the central challenge of peptide delivery: how to get therapeutic peptides past the body's protein-digesting machinery.

Understanding bioavailability is essential for interpreting peptide research because it directly affects dosing. A peptide with 1% oral bioavailability requires roughly 100 times the dose to achieve the same systemic levels as a subcutaneous injection. This has profound implications for cost, safety, and practical feasibility.

Subcutaneous (SubQ) Injection: This is the most common delivery route for research peptides. The peptide is injected into the fatty tissue layer beneath the skin, from which it is absorbed into the bloodstream through capillary networks.

Bioavailability: Typically 65–100%, depending on the peptide. Smaller peptides generally have higher subcutaneous bioavailability. The absorption rate depends on blood flow to the injection site, the peptide's molecular weight, and its physicochemical properties.

Advantages: High and predictable bioavailability, relatively simple technique, minimal first-pass metabolism, allows for depot effects (slow sustained release from the injection site).

Intramuscular (IM) Injection: Injection into muscle tissue, which has higher blood flow than subcutaneous fat, typically resulting in faster absorption.

Bioavailability: Generally 75–100%. The richer blood supply means faster absorption but also faster clearance compared to SubQ.

Key Differences: - SubQ provides slower, more sustained absorption — often preferred for peptides where steady levels are desired - IM provides faster peak concentrations — potentially preferred for peptides with acute effects - SubQ is generally less painful and easier to self-administer - Some peptides may cause more injection site reactions via one route vs. the other

Most research peptide protocols use subcutaneous injection due to ease of administration and reliable bioavailability.

Oral delivery of peptides has historically been considered nearly impossible due to three major barriers:

1. Enzymatic degradation: Stomach acid (pH 1–2) and digestive enzymes (pepsin, trypsin, chymotrypsin) rapidly break down peptide bonds. Most peptides are destroyed within minutes of entering the stomach.

2. Poor membrane permeability: Even if a peptide survives digestion, it must cross the intestinal epithelium — a barrier designed to selectively absorb small nutrients while excluding larger molecules. Peptides are generally too large and too hydrophilic to passively diffuse across this barrier.

3. First-pass metabolism: Absorbed peptides must travel through the portal vein to the liver before reaching systemic circulation. Hepatic enzymes can further metabolise peptides, reducing bioavailability.

Typical Oral Bioavailability for Peptides: Less than 1–2%. This is why most peptide therapeutics are injectable.

Notable Exception — Oral Semaglutide (Rybelsus): Novo Nordisk developed oral semaglutide using SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), a permeation enhancer that protects the peptide from degradation and facilitates absorption in the stomach. Even with this advanced formulation, oral semaglutide's bioavailability is only about 0.4–1%. The clinical dose (14mg oral) achieves similar plasma levels to the 0.5mg injectable dose — a roughly 28:1 dose ratio.

Emerging Technologies: Researchers are developing various strategies to improve oral peptide bioavailability, including nanoparticle encapsulation, mucoadhesive formulations, enteric coatings, protease inhibitors, and permeation enhancers. These technologies may eventually make oral delivery practical for a broader range of peptides.

Intranasal Delivery: The nasal mucosa provides a unique absorption route with several advantages for certain peptides: - Bioavailability typically 10–30% for small peptides - Rapid absorption (peak levels within 15–30 minutes) - Bypasses first-pass hepatic metabolism - May provide preferential delivery to the CNS via the olfactory nerve pathway (nose-to-brain delivery) - Non-invasive and easy to self-administer

Peptides Using Nasal Delivery: Selank, Semax, and oxytocin are commonly administered intranasally. The nose-to-brain pathway is particularly relevant for these neuropeptides, as it may allow higher brain concentrations than systemic injection.

Transdermal (Through the Skin): Most peptides are too large for passive transdermal absorption. However, copper peptides (GHK-Cu) and certain cosmetic peptides (Matrixyl, Argireline) are specifically designed for topical application, targeting skin-local effects rather than systemic absorption.

Sublingual/Buccal: Absorption under the tongue or through the cheek mucosa. Bioavailability varies widely (5–50%) depending on the peptide. BPC-157 is sometimes discussed in sublingual contexts, though data on this route is limited.

Summary of Bioavailability by Route: | Route | Typical Bioavailability | Speed of Onset | |-------|------------------------|----------------| | Intravenous | 100% | Immediate | | Intramuscular | 75–100% | 15–30 min | | Subcutaneous | 65–100% | 30–60 min | | Intranasal | 10–30% | 15–30 min | | Sublingual | 5–50% | 15–45 min | | Oral | <1–2% | 30–120 min | | Transdermal | Variable | Hours |

Disclaimer: This article is for educational purposes only. It is not medical advice. Route of administration affects both efficacy and safety of peptides. Consult a healthcare professional for guidance on appropriate delivery methods.